Abliva Abbased In Lundswedenis A Clinical Stage Biopharmaceutical Company Focused On Developing Treatments For Primary Mitochondrial Diseasesfounded In 2000 And Rebranded In 2020Abliva Aims To Enhance The Health And Quality Of Life For Patients Affected By These Rare Conditionswhich Currently Lack Effective Therapiesthe Company Is Listed On Nasdaq Stockholm Under The Ticker Symbol Abli And Operates As A Subsidiary Of Pharming Technologies B V Abliva S Product Pipeline Includes Kl1333A Compound In Phase 2 Clinical Trials Targeting Chronic Fatigue And Myopathy In Adult Patients With Primary Mitochondrial Diseaseanother Projectnv354Is An Energy Replacement Therapy That Has Completed Preclinical Development And Is Designed To Address Mitochondrial Disease With Neurologic Complicationsthe Company Has Formed Partnerships With Organizations Like Owl Therapeutics And Yungjin Pharm To Support Its Research And Development Initiatives
